Opening Recap

Market Pulse: Equity benchmarks drifted into a muted open as volatility from New Year moves filtered through. Bitcoin-linked names felt the pinch, but broad sentiment remains on edge.

Key Movers: MicroStrategy’s implosion on New Year’s Eve turned heads after Bitcoin exposure backfired, while Vanda’s FDA win for Nereus triggered a wave of momentum chasing.

Macro & Politics: Weight-loss drug pricing and coverage battles are gearing up, and Trump’s lunar return pitch is already stirring budget debates—and space small-caps are circling for the hype.

What’s Next: Eyes on upcoming CPI and labor figures, plus renewed chatter on drug formularies and budget priorities out of Washington.

Market Commentary

What everyone’s missing is how quickly retail FOMO morphs into systemic risk; slipping from “Retail investors beat Wall Street” to “chasing yesterday’s winners” can blow a hole in portfolios in a heartbeat. If you think Vanda’s FDA approval from Thefly.com is just biotech noise, remember that momentum traders pile in then bail just as fast—so don’t get caught holding the bag when the stop-loss hits.

Look at how Novo Nordisk enters 2026 on the defensive in the U.S. market (CNBC) then flip to Trump’s lunar comeback pledge (Barchart.com). One story is about pricing power and market share fights, the other is about government budget theater—and both hinge on political capital rather than fundamental growth. Merge those threads and you’ve got a thesis: policy hawks and populist hype will drive volatility more than earnings this quarter.

Action take-away: trim positions where regulators and politics intersect—think weight-loss formulary scraps and space plays riding a campaign wave—and redeploy capital into undervalued sectors where balance sheets actually matter. Keep stops tight and question every narrative that’s driven by headlines, not hard data.